Kim N. Chi
机构: Professor of Medicine, University of British Columbia
每年引用次数
引用次数
引用: 57,619
H-指数: 96
I10-指数 : 320
出版物: 765
Activity of enzalutamide in men with metastatic castration resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
Heather H Cheng , Roman Gulati , Arun Azad , Rosa Nadal
Prostate Cancer and Prostatic Diseases 18 ( 2) 122 -127
63
2015
Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia.
ABDULWAHAB J. AL-TOURAH , NEVIN MURRAY , CHRIS COPPIN , CHRISTIAN KOLLMANNSBERGER
The Journal of Urology 174 ( 6) 2209 -2213
15
2005
Asian Race and Impact on Outcomes After Radical Radiotherapy for Localized Prostate Cancer
ADA MAN , TOM PICKLES , KIM N. CHI ,
The Journal of Urology 170 ( 3) 901 -904
24
2003
A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.
Richard Klasa , Anthony W. Tolcher , Nevin Murray , Daniel E. Lopes de Menezes
Clinical Cancer Research 7 ( 12) 3920 -3927
182
2001
Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.
Kim N. Chi , Martin E. Gleave , Hideaki Miyake
Clinical Cancer Research 6 ( 5) 1655 -1663
158
2000
Managing CRPC: improving symptoms, survival, or both?
Kim N. Chi
Oncology 25 ( 14) 1387
2011
Plasma exosome microRNAs in patients with advanced renal cell carcinoma treated with nivolumab and ipilimumab: Potential biomarkers of response to therapy.
Bernhard J. Eigl , Lucia Nappi , Christian K. Kollmannsberger , Kim N. Chi
Journal of Clinical Oncology 39 338 -338
2021
Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer.
Hala T. Borno , Ajjai S. Alva , Alexander W. Wyatt , Alexander W. Wyatt
Cancer 127 ( 12) 1965 -1973
2021
5-hydroxymethylcytosine as a liquid biopsy biomarker in mCRPC.
Joshi J. Alumkal , David A. Quigley , Alexander W. Wyatt , Felix Y Feng
Journal of Clinical Oncology 39 148 -148
2021
Longer follow-up data of circulating miR371a-3p expression across the spectrum of germ cell tumors (GCT).
Siamak Daneshmand , Bernhard J. Eigl , Robert James Hamilton , Lucia Nappi
Journal of Clinical Oncology 39 379 -379
2021
Concordance of BRCA1, BRCA2 (BRCA), and ATM mutations identified in matched tumor tissue and circulating tumor DNA (ctDNA) in men with metastatic castration-resistant prostate cancer (mCRPC) screened in the PROfound study.
Claire Corcoran , Simon Dearden , Elizabeth Harrington , Zhongwu Lai
Journal of Clinical Oncology 39 26 -26
1
2021
AMPLITUDE: A study of niraparib in combination with abiraterone acetate plus prednisone (AAP) versus AAP for the treatment of patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC).
Dana E. Rathkopf , Heather H. Cheng , Shahneen Kaur Sandhu , Neeraj Agarwal
Journal of Clinical Oncology 39
2021
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)
Fred Saad , Marc De Meulder , Eugene Zhu , Rao N.V.S. Mamidi
Cancer Chemotherapy and Pharmacology 88 ( 1) 25 -37
2021
Finding the optimal treatment sequence in metastatic castration-resistant prostate cancer—a narrative review
Kim N. Chi , Daniel J. Khalaf , Corinne Maurice Dror
Translational Andrology and Urology
2021
Abstract PO-077: Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using 177Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH) - Trial in progress
Matthias Eiber , Scott Tagawa , Neil Fleshner , Johannes Czernin
Clinical Cancer Research 27
2021
Germline DNA repair mutations in metastatic castration-resistant prostate cancer: Therapy response and applicability of circulating tumor DNA.
Werner J. Struss , Matti Annala , Evan W Warner , Kevin Beja
Journal of Clinical Oncology 35 140 -140
2
2017
PACIFIC trial: A randomized phase II study of apatorsen and abiraterone in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) who have had PSA progression while receiving abiraterone (ABI).
Kim N. Chi , Mark T. Fleming , Katherine Sunderland , Costantine Albany
Journal of Clinical Oncology 35 146 -146
8
2017
Phase Ib study of apalutamide (APA) with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Update on safety and efficacy.
Edwin M. Posadas , Kim N. Chi , Ronald De Wit , Maja J. De Jonge
Journal of Clinical Oncology 35 173 -173
3
2017
Circulating tumor DNA (ctDNA) and correlations with clinical prognostic factors in patients with metastatic castration-resistant prostate cancer (mCRPC).
Daniel Khalaf , Matti Annala , Kevin Beja , Gillian Vandekerkhove
Journal of Clinical Oncology 35 186 -186
2
2017
Molecular dissection of primary mediastinal germ cell tumors.
Lucia Nappi , Matti Annala , Gillian Vandekerkhove , Ladan Fazli
Journal of Clinical Oncology 35 417 -417
4
2017